JP2023509675A5 - - Google Patents

Info

Publication number
JP2023509675A5
JP2023509675A5 JP2022540709A JP2022540709A JP2023509675A5 JP 2023509675 A5 JP2023509675 A5 JP 2023509675A5 JP 2022540709 A JP2022540709 A JP 2022540709A JP 2022540709 A JP2022540709 A JP 2022540709A JP 2023509675 A5 JP2023509675 A5 JP 2023509675A5
Authority
JP
Japan
Prior art keywords
individual particles
cannabinoid oil
microcrystalline cellulose
composition
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022540709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/050245 external-priority patent/WO2021140183A1/en
Publication of JP2023509675A publication Critical patent/JP2023509675A/ja
Publication of JP2023509675A5 publication Critical patent/JP2023509675A5/ja
Pending legal-status Critical Current

Links

JP2022540709A 2020-01-08 2021-01-08 胃腸障害を治療するための経口用固形カンナビノイド油組成物 Pending JP2023509675A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958392P 2020-01-08 2020-01-08
US62/958,392 2020-01-08
PCT/EP2021/050245 WO2021140183A1 (en) 2020-01-08 2021-01-08 Oral solid cannabinoid oil composition for treating gastrointestinal disorders

Publications (2)

Publication Number Publication Date
JP2023509675A JP2023509675A (ja) 2023-03-09
JP2023509675A5 true JP2023509675A5 (https=) 2024-01-16

Family

ID=74236138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540709A Pending JP2023509675A (ja) 2020-01-08 2021-01-08 胃腸障害を治療するための経口用固形カンナビノイド油組成物

Country Status (8)

Country Link
US (2) US12186281B2 (https=)
EP (1) EP4087547A1 (https=)
JP (1) JP2023509675A (https=)
CN (1) CN114845705A (https=)
AU (1) AU2021206021A1 (https=)
BR (1) BR112022010335A2 (https=)
CA (1) CA3164489A1 (https=)
WO (1) WO2021140183A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021417405A1 (en) * 2021-01-08 2023-06-22 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating central nervous system disorders
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
US8808736B2 (en) * 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
WO2012109216A1 (en) * 2011-02-11 2012-08-16 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
CA2909591C (en) * 2013-04-23 2017-03-28 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
AU2017216928B2 (en) 2016-02-11 2018-09-20 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US20190091198A1 (en) * 2016-03-28 2019-03-28 Lihi BAR-LEV SCHLEIDER Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract
WO2017193072A1 (en) 2016-05-06 2017-11-09 Harvest Direct Enterprises Llc The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals
MX382609B (es) * 2016-07-25 2025-03-13 Canopy Growth Corp Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
CA3036585A1 (en) 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US20200163931A1 (en) 2016-10-12 2020-05-28 Columbia Care Llc Oral composition of extracted cannabinoids and methods of use thereof
CN108853079A (zh) * 2017-05-15 2018-11-23 汉义生物科技（北京）有限公司 大麻素类化合物在治疗肠易激综合征中的应用
CA3078549A1 (en) * 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
WO2019082171A1 (en) * 2017-10-27 2019-05-02 Alvit Pharma ORAL CANNABINOID COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY
WO2019234743A1 (en) 2018-06-06 2019-12-12 Icdpharma Ltd. Anti-inflammatory synergistic compositions comprising cannabinoids and licorice
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations

Similar Documents

Publication Publication Date Title
JP2023509675A5 (https=)
DE19940944B4 (de) Retardierte, orale, pharmazeutische Darreichungsformen
EP3154523B1 (en) Formulation for oral administration containing mesalazine
JP2007507553A5 (https=)
JPH04234313A (ja) 徐放性組成物
RU2744576C2 (ru) Пероральные фармацевтические композиции месалазина
JP2016516698A5 (https=)
JP2014501267A (ja) メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法
PT99699A (pt) Processo de producao de uma forma de dosagem oral de libertacao por fases a base de antagonista de h2' nomeadamente cimetidina
CN109152772B (zh) 烟酰胺的口服药物组合物
CN114845705A (zh) 用于治疗胃肠疾病的口服固体大麻素油组合物
CA3160869C (en) Dosage form for use in treating or preventing of a disease
SI21301A (sl) Farmacevtska oblika z nadzorovanim sproščanjem
JP2024502309A5 (https=)
KR20100130882A (ko) 서방성 비스테로이드성 소염제 조성물 및 그 제조방법
US20090186087A1 (en) Enteric sustained-release coated core and pharmaceutical dosage form and method for manufacturing the same
Percel et al. Timed pulsatile drug delivery system
SI21638A (sl) Farmacevtska oblika z nadzorovanim sproščanjem ketoprofena
JP2025537377A (ja) 薬剤搭載改変放出ペレット
HK40005191B (en) Oral pharmaceutical compositions of nicotinamide